Serotonergic Mechanisms in the Regulation of the Human Coronary Circulation in Vivo

References

• Ashton J. H., Benedict C. R., Fitzgerald C, Raheja S., Taylor A., Campbell W., Buja LM., Willerson J. T. Serotonin is a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572–578
   PubMed Web of Science ®Google Scholar
• Ashton J. H., Ogletree M. L., Michel I. M., Taylor A. L., Raheja S., Schmitz J., Buja L. M., Campbell W. B., Willerson J. T. Cooperative mediation by serotonin S2 and thromboxane A2 prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987; 76: 952–959
   PubMed Web of Science ®Google Scholar
• Bove A. A., Dewey J. D. Effects of serotonin and histamine on proximal and distal coronary vasculature in dogs: Comparison with alpha-adrenergic stimulation. Am. J. Cardiol 1983; 52: 1333–1339
   PubMed Web of Science ®Google Scholar
• Brum J. M., Sufan Q., Lane G., Bove A. A. Increased vasoconstrictor activity of proximal coronary arteries with endothelial damage in intact dogs. Circulation 1984; 70: 1066–1073
   PubMed Web of Science ®Google Scholar
• Bush L. R., Campbell W. B., Kern K., Tilton G. D., Apprill P., Ashton J., Schmitz J., Buja L. M., Willerson J. T. The effects of alpha2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ. Res 1984; 55: 642–652
   PubMed Web of Science ®Google Scholar
• Chu A., Cobb F. R. Vasoactive effects of serotonin on proximal coronary arteries in awake dogs. Circ. Res 1987; 61(II)II-81–II-87
   Google Scholar
• Cohen R. A., Shepherd J. T., Vanhoutte P. M. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983; 221: 273–274
   PubMed Web of Science ®Google Scholar
• De Caterina R., Carpeggiani C., L'Abbate A. A double-blind, placebo controlled study of ketanserin in patients with Prinzmetal's angina: Evidence against a role for serotonin in the genesis of coronary vasospasm. Circulation 1984; 69: 889–894
   PubMed Web of Science ®Google Scholar
• De Clerck F., Xhonneux B., Chaffoy de Courcelles D. Functional expression of the amplification reaction between serotonin and epinephrine on platelets. J. Cardiovasc. Pharmacol 1988; 11: S1–S8, suppl I
   PubMed Web of Science ®Google Scholar
• Feinstein M. B. The role of calcium in blood platelet function. Calcium in Drug A., G. Weiss. Plenum Press, New York 1978; 197–239
   Google Scholar
• Folts J. D., Crowell EJ., Jr., Rowe C. G. Platelet aggregation in partially obstructed vessels and its elimination by aspirin. Circulation 1976; 54: 365–370
   PubMed Web of Science ®Google Scholar
• Golino P., Ashton J. H., Buja L. M., Taylor A. L., Mc Natt J., Rosolowsky M, Campbell W. B., Willerson J. T. Local platelet activation causes vasoconstriction of large epicar-dial canine coronary arteries in vivo Thromboxane A2 and serotonin are possible mediators. Circulation 1989; 79: 154–166
   PubMed Web of Science ®Google Scholar
• Golino P., Buja L. M., Yao S. K., McNatt J., Willerson J. T. Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: Further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo. J. Am. Coll. Cardiol 1990; 15: 718–726
   PubMed Web of Science ®Google Scholar
• Golino P., Piscione F., Willerson J. T., Cappelli-Bigazzi M., Focaccio A., Villari B., Indolfi C, Russolillo E., Condorelli M., Chiariello M. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 1991; 324: 641–648
   PubMed Web of Science ®Google Scholar
• Golino P., Cappelli-Bigazzi M., Ambrosio G., Ragni M., Russolillo E., Condorelli M., Chiariello M. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ. Res. 1992a; 71: 1447–1453
   PubMed Web of Science ®Google Scholar
• Houston D. S., Vanhoutte P. M. Pathophysiologic significance of 5-hydroxytryptamine in the periphery. In The Peripheral Actions of 5-Hydrozytryptamine, J. R. Fozard. Oxford University Press, Oxford 1989; 377–406
   Google Scholar
• Ichikawa Y., Yokoyama M., Akita H., Fukuzaki H. Constriction of a large coronary artery contributes to serotonin-induced myocardial ischemia in the dog with pliable coronary stenosis. J. Am. Coll. Cardiol 1989; 14: 449–459
   PubMed Web of Science ®Google Scholar
• Lamping K. G., Dole W. P. Flow-mediated dilation attenuates constriction of large coronary arteries to serotonin. Am. J. Physiol 1988; 255: H1317–H1324
   PubMed Web of Science ®Google Scholar
• Lamping K. G., Marcus M. L., Dole W. P. Removal of the endothelium potentiates canine large coronary artery constrictor responses to 5-hydroxytryptamine in vivo. Circ. Res. 1985; 57: 46–54
   PubMed Web of Science ®Google Scholar
• Mc Fadden E. P., Clarke J. G., Davies G. J., Kaski J. C., Haider A. W., Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N. Engl. J. Med. 1991; 324: 648–654
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Snyder S. H. Multiple serotonin receptors: Differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide and 3H-spiroperidol. Mol. Pharmacol 1979; 16: 687–699
   PubMed Web of Science ®Google Scholar
• Rapport M. M. Serum vasoconstrictor (serotonin). V. The presence of creatinine in the complex: A proposed study of the vasoconstrictor principle. J. Biol. Chem. 1949; 180: 961–969
   PubMed Web of Science ®Google Scholar
• Rubanyi G. M., Frye R. L., Holmes D. R., Vanhoutte P. M. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J. Am. Coll. Cardiol 1987; 9: 1243–1249
   PubMed Web of Science ®Google Scholar
• van den Berg E. K., Schmitz J. M., Benedict C. R., Malloy C. R., Willerson ]. T., Dehemer G. J. Transcardiac serotonin concentration is increased in patients with limiting angina and complex coronary lesion morphology. Circulation. 1989; 79: 116–124
   PubMed Web of Science ®Google Scholar
• Vanhoutte P. M. Serotonin and the Cardiovascular System. Raven Press, New York 1985
   Google Scholar
• Van Nueten J. M., Janssen P. A. J., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J. Pharmacol. Exp. Ther. 1981; 218: 217–230
   PubMed Web of Science ®Google Scholar
• Zucker M. B., Nachamias V. T. Platelet activation. Arteriosclerosis 1985; 5: 2–18
   PubMedGoogle Scholar